Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2001 / Cilt: 27 - Sayı: 3

Could sildenafil citrate useful at etiologic discriminant in patients with erectile dysfunction?

Sildenafil sitrat erektil disfonksiyonlu hastalarda etiyolojik ayırımda kullanılabilir mi?

Pages
311–315
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall response to sildenafil was 76.6 %.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this open and prospective study, we aimed to evaluate whether sildenafil citrate is useful as a diagnostic tool or not. 82 male patients with erectile dysfunction, who admitted to our andrology polyclinic between July 1999 and May 2000 were included in this study.
📊
Key Findings & Data:Erectile response to intracavernosal drug injections and sildenafil were categorized from E0 to E5.
💡
Conclusion & Impact:Overall response to sildenafil was 76.6 %.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Tanı · İmpotans · Piperazinler

Abstract

In this open and prospective study, we aimed to evaluate whether sildenafil citrate is useful as a diagnostic tool or not. 82 male patients with erectile dysfunction, who admitted to our andrology polyclinic between July 1999 and May 2000 were included in this study. Each patient underwent comprehensive evaluation consisting of a detailed history, International Index of Erectile Function, physical examination, psychiatric counseling, blood biochemistry panel and testosterone level determinations, an intracavernosal papaverine injection test, penil colour Doppler sonography and some patients underwent DICC. Erectile response to intracavernosal drug injections and sildenafil were categorized from E0 to E5. E4-5 accepted as complete response and E3 accepted as partial response. Patients mean age was 50.7$\pm$1.0 years and the duration of their erectile dysfunction was 3.2$\pm$0.3 years. Medical histories of the patients revealed diabetes mellitus in 11 cases (13.4 %), hypertension in 5 cases (6.1 %), chronic obstructive pulmonary disease in 5 cases (6.1 %), and coronary heart disease in 1 case (1.2 %). Etiologic classification of erectile dysfunction in the 82 patients was as follows: psychogenic in 30 cases (36.6%), corporacavernosal failure in 30 cases (36.6 %), and arterial insufficiency in 22 cases (26.8%). Overall response to sildenafil was 76.6 %. These responses were complete in %58.5 cases and partial in %17.1 cases. Complete response was 50% in vasculogenic group and was 73,3% in psychogenic group. Partial response was 15,4% in vasculogenic group and was 20% in psychogenic group. As a result, erectile response to sildenafil citrate could not found as an appropriate test for etiologic evaluation of erectile dysfunction.

Özet

Bu açık ve prospektif çalışmada, sildenafil sitratın erektil disfonksiyonda tanısal amaçlı olarak kullanılabilirliğini saptamak amaçlanmıştır. Temmuz 1999-Mayıs 2000 tarihleri arasında Androloji polikliniğimize erektil disfonksiyon yakınması ile başvuran 82 hasta çalışma kapsamına alındı. Bütün hastalar öykü, "International Index of Erectile Function" skoru, fizik inceleme, serum testosteron ve kan biyokimyasal incelemesi, intrakavernozal papaverin testi, renkli dupleks Doppler sonografi ve gerekenlere ise dinamik infüzyon kavernozometri-kavernozografiyi içeren tam bir değerlendirmeye tabi tutuldu. Papaverin testi ve sildenafil ile elde edilen ereksiyonlar E0-E5 arasında katagorize edildi. E4-5 ereksiyonlar tam yanıt, E3 ereksiyon ise kısmı yanıt olarak kabul edildi. Hastaların yaş ortalaması 50.7$\pm$1.0 ve yakınma süresi 3.2$\pm$0.3 yıl idi. Hastaların 11 tanesinde (%13.4) diabetes mellitus, 5'inde (%6.1) hipertansiyon, 5'inde (%6.1) KOAH, 1'inde ise (%1.2) koroner kalp hastalığı öyküsü vardı. 82 hastanın etyolojik dağılımı 30 hasta psikojenik (%36.6), 30 hastada korporakavernozal yetmezlik (%36.6), 22 hastada arteriyel yetmezlik (%26.8) şeklinde idi. Sildenafil ile %76.6 oranında yanıt alındı. Bu hastaların %58.5 da tam, %17.1 de ise kısmı yanıt şeklinde idi. Tam yanıt vaskülojenik etyolojili grupta %50, psikojeniklerde ise %73,3 idi. Kısmı yanıt ise vaskülojenik etiyolojili grupta %15,4 , psikojeniklerde ise %20 idi. Sildenafile alınan erektil yanıt erektil disfonksiyonun etiyolojik değerlendirilmesinde kullanılabilecek uygun bir test değildir.

🔖

Cite This Article

TARHAN, F., BAYKAL, H., ERYILDIRIM, B., ERGEN, M., KUYUMCUOĞLU, U. (2001). Could sildenafil citrate useful at etiologic discriminant in patients with erectile dysfunction?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 27 - Sayı: 3, 311–315. https://ajindex.com/articles/328878

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. NIH Concensus Conference: Impotence. NIH Concensus Development Panel on Impotence. JAMA, 270: 83-90, 1993
  2. Feldman HA, Goldstein I, Hatzichritou DG et al: Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol, 151: 54-61, 1994 3- Jarow JP, Burnett AL, Geringer AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment J Urol, 162: 722-5, 1999
  3. Conti CR, Pepine CJ, Sweeney M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic he-art disease. Am J Cardiol 83: 29C-34C, 1999
  4. Morales A, Gingell C, Collins M, et al: Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res, 10: 69-73, 1998
  5. Rosen RC, Riley A, Wzgner G et al: The Inter-national Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 49: 822-830, 1997
  6. Jarow JP, Nana-Sinkam P, Sabbag M, Eskew A: Outcome analysis of goal directed therapy for impotence. J Urol, 155: 1609-12, 1996
  7. Goldstein I, Lue TF, Padma-Nathan H, et al: Oral sildenafil in the treatment of erectile dys-function. Sildenafil Study Group. N Engl J Med, 338: 1397-404, 1998
  8. Marks LS, Duda C, Dorey FJ, et al: Treatment of erectile dysfunction with sildenafil. Urology, 53: 19-24, 1999
  9. Padma-Nathan H, Steers WD, Wicker PA: Ef-ficacy and safety of oral sildenafil in the treat-ment of erectile dysfunction: a double-blind, pla-cebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract, 52: 375-9, 1998
  10. McMahon CG, Samali R, Johnson H: Treat-ment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple a-gent intracorporeal injection therapy. J Urol, 162: 1992-7, 1999
  11. Montorsi F, McDermott TE, Morgan R, et al: Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology, 53: 1011-8, 1999
  12. Shabsigh R: Efficacy of sildenafil citrate (VIAGRA) is not affected by etiology of erectile dysfunction. Int J Clin Pract Suppl; 102: 19-20, 1999.